Rudolf Uher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3831220/publications.pdf

Version: 2024-02-01

		6233	7333
314	27,719	80	152
papers	citations	h-index	g-index

392	392	392	29016
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.1	0
2	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
3	The Developmental Brain Age Is Associated With Adversity, Depression, and Functional Outcomes Among Adolescents. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 406-414.	1.1	13
4	â€œOne Degree of Separationâ€• A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. Canadian Journal of Psychiatry, 2022, , 070674372110706.	0.9	6
5	Role of Polygenic Risk Score in the Familial Transmission of Bipolar Disorder in Youth. JAMA Psychiatry, 2022, 79, 160.	6.0	19
6	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	1.3	3
7	The Text4HealthyAging Program: An Evidence-Based Text Messaging Innovation to Support Healthy Urban Aging in Canada and Australia. Gerontology and Geriatric Medicine, 2022, 8, 233372142210813.	0.8	4
8	Time for united action on depression: a Lancetâ€“World Psychiatric Association Commission. Lancet, The, 2022, 399, 957-1022.	6.3	292
9	The role of bipolar polygenic risk score in the familial transmission of bipolar disorderâ€”An updated analysis. Bipolar Disorders, 2022, 24, 437-440.	1.1	4
10	Sex-Specific Transmission of Anxiety Disorders From Parents to Offspring. JAMA Network Open, 2022, 5, e2220919.	2.8	6
11	Youth Experience Tracker Instrument: A selfâ€report measure of developmental antecedents to severe mental illness. Microbial Biotechnology, 2021, 15, 676-685.	0.9	3
12	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	2.4	16
13	Prevalence of attentionâ€deficit/hyperactivity disorder in people with mood disorders: A systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2021, 143, 380-391.	2.2	31
14	A Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2021, 47, 1342-1350.	2.3	17
15	CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ, The, 2021, 373, n857.	3.0	65
16	Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). BMJ Open, 2021, 11, e049093.	0.8	9
17	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CANâ€BIND 1 report. Personality and Mental Health, 2021, 15, 273-282.	0.6	1
18	The association between genetically determined ABO blood types and major depressive disorder. Psychiatry Research, 2021, 299, 113837.	1.7	4

#	Article	IF	Citations
19	Attention-deficit/hyperactivity disorder and other neurodevelopmental disorders in offspring of parents with depression and bipolar disorder. Psychological Medicine, 2021, , 1-8.	2.7	7
20	Parental Overprotection and Sleep Problems in Young Children. Child Psychiatry and Human Development, 2021, , 1.	1.1	1
21	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS ONE, 2021, 16, e0253023.	1.1	4
22	Estimating Severity of Depression From Acoustic Features and Embeddings of Natural Speech. , 2021, , .		5
23	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	2.4	3
24	Transcriptome-based polygenic score links depression-related corticolimbic gene expression changes to sex-specific brain morphology and depression risk. Neuropsychopharmacology, 2021, 46, 2304-2311.	2.8	5
25	Risk and protective factors for mental disorders beyond genetics: an evidenceâ€based atlas. World Psychiatry, 2021, 20, 417-436.	4.8	127
26	The Genetic Architecture of Depression in Individuals of East Asian Ancestry. JAMA Psychiatry, 2021, 78, 1258.	6.0	88
27	Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study. Journal of Psychiatric Research, 2021, 142, 321-327.	1.5	1
28	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	1.3	8
29	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	2.7	38
30	Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram. Psychological Medicine, 2021, , 1-9.	2.7	3
31	Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics Journal, 2020, 20, 329-341.	0.9	45
32	Observed psychopathology in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. Psychological Medicine, 2020, 50, 1050-1056.	2.7	21
33	Affective lability in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. European Child and Adolescent Psychiatry, 2020, 29, 445-451.	2.8	9
34	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	2.7	17
35	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. Biological Psychiatry, 2020, 87, 419-430.	0.7	27
36	Prospective Association between Childhood Behavioral Inhibition and Anxiety: a Meta-Analysis. Research on Child and Adolescent Psychopathology, 2020, 48, 57-66.	1.4	57

#	Article	IF	Citations
37	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	2.8	49
38	Active behaviors and screen time in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. Psychiatry Research, 2020, 285, 112709.	1.7	1
39	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	2.0	4
40	Neurodevelopmental and genetic determinants of exposure to adversity among youth at risk for mental illness. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2020, 61, 536-544.	3.1	24
41	INTERGENERATIONAL TRANSMISSION OF PSYCHOPATHOLOGY AND EARLY IDENTIFICATION OF RISK: NEW INSIGHTS FROM THE STUDY OF CHILD AND ADOLESCENT OFFSPRING OF PARENTS LIVING WITH DEPRESSION, BIPOLAR DISORDER, AND SCHIZOPHRENIA. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S305.	0.3	0
42	26.4 EARLY TRANSDIAGNOSTIC IDENTIFICATION OF RISK FOR MAJOR MOOD AND PSYCHOTIC DISORDERS. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S306.	0.3	0
43	Cognition in offspring of parents with psychotic and non-psychotic severe mental illness. Journal of Psychiatric Research, 2020, 130, 306-312.	1.5	5
44	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. Schizophrenia Research, 2020, 226, 176-183.	1.1	11
45	Early Identification of Risk for Major Depressive Disorder in the FORBOW Project. Biological Psychiatry, 2020, 87, S5.	0.7	0
46	Genetic counselling for the prevention of mental health consequences of cannabis use: A randomized controlled trialâ€within†cohort. Microbial Biotechnology, 2020, 15, 1306-1314.	0.9	1
47	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. Biological Psychiatry, 2020, 87, S431.	0.7	1
48	Cognitive-behavioural interventions for prevention and treatment of anxiety in young children: A systematic review and meta-analysis. Clinical Psychology Review, 2020, 81, 101904.	6.0	19
49	Diagnoses. Mental Health and Illness Worldwide, 2020, , 3-15.	0.1	1
50	Psychotic symptoms are associated with lower cortical folding in youth at risk for mental illness. Journal of Psychiatry and Neuroscience, 2020, 45, 125-133.	1.4	8
51	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	2.8	23
52	Assessment of Psychopathology. JAMA Psychiatry, 2020, 77, 557.	6.0	12
53	Visual memory and psychotic symptoms in youth. Cognitive Neuropsychiatry, 2020, 25, 231-241.	0.7	1
54	Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nature Genetics, 2020, 52, 437-447.	9.4	207

#	Article	IF	Citations
55	Visual memory in offspring of parents with mental illness. Psychiatry Research, 2020, 286, 112813.	1.7	2
56	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	2.4	33
57	Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. Molecular Psychiatry, 2020, 25, 1430-1446.	4.1	116
58	Reliability of multimodal MRI brain measures in youth at risk for mental illness. Brain and Behavior, 2020, 10, e01609.	1.0	8
59	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	1.1	9
60	Dr Uher and Colleagues Reply. Journal of Clinical Psychiatry, 2020, 82, .	1.1	1
61	Diagnoses. Mental Health and Illness Worldwide, 2020, , 1-13.	0.1	0
62	Larger right inferior frontal gyrus volume and surface area in participants at genetic risk for bipolar disorders. Psychological Medicine, 2019, 49, 1308-1315.	2.7	20
63	Clinical course predicts long-term outcomes in bipolar disorder. Psychological Medicine, 2019, 49, 1109-1117.	2.7	6
64	Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models. Translational Psychiatry, 2019, 9, 187.	2.4	51
65	Brain age in bipolar disorders: Effects of lithium treatment. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1179-1188.	1.3	49
66	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	2.4	33
67	T75GWAS AND PATHWAY ENRICHMENT ANALYSIS IN ADVERSE DRUG REACTIONS IN DEPRESSION. European Neuropsychopharmacology, 2019, 29, S255-S256.	0.3	0
68	META-ANALYSIS OF CYP2C19 ASSOCIATION WITH EFFICACY AND SIDE EFFECTS OF CITALOPRAM AND ESCITALOPRAM USING DATA FROM GENOME-WIDE ASSOCIATION STUDIES. European Neuropsychopharmacology, 2019, 29, S808.	0.3	0
69	F52. WHO CO-PARENT CHILDREN WITH MOTHERS AND FATHERS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER? CHARACTERIZING INDIVIDUALS WHO HAVE CHILDREN TOGETHER WITH INDIVIDUALS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER. Schizophrenia Bulletin, 2019, 45, S275-S275.	2.3	0
70	Basic symptoms in offspring of parents with mood and psychotic disorders. BJPsych Open, 2019, 5, e54.	0.3	10
71	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. British Journal of Psychiatry, 2019, 215, 494-501.	1.7	10
72	Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults. JAMA Psychiatry, 2019, 76, 399.	6.0	399

#	Article	IF	Citations
73	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. Frontiers in Psychiatry, 2019, 10, 174.	1.3	45
74	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S254.	0.7	0
75	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. Biological Psychiatry, 2019, 85, S344-S345.	0.7	0
76	Polygenic risk for circulating reproductive hormone levels and their influence on hippocampal volume and depression susceptibility. Psychoneuroendocrinology, 2019, 106, 284-292.	1.3	18
77	Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts. Biological Psychiatry, 2019, 85, 1065-1073.	0.7	25
78	Sleep in Offspring of Parents With Mood Disorders. Frontiers in Psychiatry, 2019, 10, 225.	1.3	13
79	Evidence of causal effect of major depression on alcohol dependence: findings from the psychiatric genomics consortium. Psychological Medicine, 2019, 49, 1218-1226.	2.7	74
80	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	7
81	Brain Age in Early Stages of Bipolar Disorders or Schizophrenia. Schizophrenia Bulletin, 2019, 45, 190-198.	2.3	94
82	T38GENETIC COUNSELLING FOR THE PREVENTION OF MENTAL HEALTH CONSEQUENCES OF CANNABIS USE: A RANDOMIZED CONTROLLED TRIAL. European Neuropsychopharmacology, 2019, 29, S237.	0.3	2
83	M31 IMPACT OF CYP2C19 AND CYP2D6 GENE VARIANTS ON PLASMA LEVELS AND TREATMENT RESPONSE IN PATIENTS RECEIVING ESCITALOPRAM AND ARIPIPRAZOLE FOR MAJOR DEPRESSION: RESULTS FROM THE CAN-BIND-1 COHORT. European Neuropsychopharmacology, 2019, 29, S183.	0.3	0
84	T2. Brain Age in Bipolar Disorders - Effects of Lithium Treatment. Biological Psychiatry, 2019, 85, S130.	0.7	0
85	Offspring of parents with schizophrenia, bipolar disorder, and depression. Psychiatric Genetics, 2019, 29, 160-169.	0.6	49
86	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	2.7	22
87	Association of Whole-Genome and NETRIN1 Signaling Pathwayâ€"Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 91-100.	1.1	16
88	Like father like daughter: sex-specific parent-of-origin effects in the transmission of liability for psychotic symptoms to offspring. Journal of Developmental Origins of Health and Disease, 2019, 10, 100-107.	0.7	9
89	Cognitive Performance in First-Degree Relatives of Individuals With vs Without Major Depressive Disorder. JAMA Psychiatry, 2019, 76, 297.	6.0	34
90	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	1.7	44

#	Article	IF	Citations
91	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	61
92	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	1.1	16
93	T233. Obesity and Brain Age in First Episode of Schizophrenia-Spectrum Disorders â€“ Effects of Antipsychotic Medications. Biological Psychiatry, 2018, 83, S219.	0.7	0
94	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Scientific Reports, 2018, 8, 5530.	1.6	51
95	Obesity, dyslipidemia and brain age in first-episode psychosis. Journal of Psychiatric Research, 2018, 99, 151-158.	1.5	80
96	Geneâ€“environment interplay in the etiology of psychosis. Psychological Medicine, 2018, 48, 1925-1936.	2.7	89
97	Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring. JAMA Psychiatry, 2018, 75, 176.	6.0	126
98	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	9.4	2,224
99	Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. Biological Psychiatry, 2018, 84, 138-147.	0.7	87
100	Anxiety disorders and childhood maltreatment as predictors of outcome in bipolar disorder. Journal of Affective Disorders, 2018, 225, 337-341.	2.0	14
101	Interaction between childhood maltreatment on immunogenetic risk in depression: Discovery and replication in clinical case-control samples. Brain, Behavior, and Immunity, 2018, 67, 203-210.	2.0	31
102	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics Journal, 2018, 18, 413-421.	0.9	40
103	Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. Research Integrity and Peer Review, 2018, 3, 9.	2.2	28
104	Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts. PLoS ONE, 2018, 13, e0203896.	1.1	37
105	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.3	64
106	Psychological interventions in offspring of parents with bipolar disorder. , 2018, , 247-264.		1
107	Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood. British Journal of Psychiatry, 2018, 213, 555-560.	1.7	32
108	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	2.4	19

#	Article	IF	Citations
109	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. Journal of Psychiatric Research, 2018, 105, 17-22.	1.5	18
110	Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. BMJ Open, 2018, 8, e025266.	0.8	10
111	No Association Between Antidepressant Efficacy and rs28365143 in Corticotropin-Releasing Hormone Binding Protein in a Large Meta-Analysis. American Journal of Psychiatry, 2018, 175, 575-576.	4.0	1
112	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286
113	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	13.7	544
114	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	2.5	71
115	The Effect of Parental Modeling on Child Pain Responses: The Role of Parent and Child Sex. Journal of Pain, 2017, 18, 702-715.	0.7	35
116	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	2.0	202
117	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	0.9	0
118	The genomeâ€wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 427-434.	1.1	16
119	Etiology in psychiatry: embracing the reality of polyâ€geneâ€environmental causation of mental illness. World Psychiatry, 2017, 16, 121-129.	4.8	202
120	Hot and cold executive functions in youth with psychotic symptoms. Psychological Medicine, 2017, 47, 2844-2853.	2.7	21
121	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	5.8	144
122	Autism risk following antidepressant medication during pregnancy. Psychological Medicine, 2017, 47, 2787-2796.	2.7	51
123	Disruptive mood dysregulation disorder in offspring of parents with depression and bipolar disorder. British Journal of Psychiatry, 2017, 210, 408-412.	1.7	14
124	Prevalence of current anxiety disorders in people with bipolar disorder during euthymia: a meta-analysis. Psychological Medicine, 2017, 47, 1107-1115.	2.7	39
125	An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biological Psychiatry, 2017, 82, 322-329.	0.7	84
126	Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 235-250.	1.1	10

#	Article	IF	Citations
127	New Insights Into The Pharmacogenomics Of Antidepressant Response From The Gendep And Star*D Studies: Results Of Rare Variant Analysis And High-Density Imputation. European Neuropsychopharmacology, 2017, 27, S443-S444.	0.3	0
128	Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. JAMA Psychiatry, 2017, 74, 1214.	6.0	174
129	255. Greater Gyrification of the Inferior Frontal Gyrus as a Marker of Genetic Risk for Bipolar Disorders. Biological Psychiatry, 2017, 81, S105.	0.7	0
130	785. Structural Properties and Connectivity of the Right Inferior Frontal Gyrus in Individuals at Genetic Risk for Bipolar Disorders. Biological Psychiatry, 2017, 81, S319.	0.7	1
131	Adversity, Parental Mental Illness, and Risk of Depression in Youth. European Psychiatry, 2017, 41, S220-S220.	0.1	1
132	Hair Cortisol in Twins: Heritability and Genetic Overlap with Psychological Variables and Stress-System Genes. Scientific Reports, 2017, 7, 15351.	1.6	50
133	Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals. British Journal of Psychiatry, 2017, 211, 70-76.	1.7	49
134	Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring. JAMA Psychiatry, 2017, 74, 1031.	6.0	34
135	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. European Neuropsychopharmacology, 2017, 27, S582-S583.	0.3	0
136	Childhood maltreatment and the medical morbidity in bipolar disorder: a caseâ€“control study. International Journal of Bipolar Disorders, 2017, 5, 30.	0.8	12
137	Polygenic interactions with environmental adversity in the aetiology of major depressive disorder. Psychological Medicine, 2016, 46, 759-770.	2.7	176
138	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. Journal of Psychiatric Research, 2016, 78, 94-102.	1.5	149
139	Personâ€centered measurementâ€based care for depression. World Psychiatry, 2016, 15, 238-239.	4.8	6
140	Specific anxiety disorders and subsequent risk for bipolar disorder: a nationwide study. World Psychiatry, 2016, 15, 187-188.	4.8	7
141	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	0.9	746
142	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	0.9	340
143	Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-Î² mRNA Levels Accurately Predict Treatment Response in Depressed Patients. International Journal of Neuropsychopharmacology, 2016, 19, pyw045.	1.0	100
144	Long-term effects of depression treatment. Lancet Psychiatry,the, 2016, 3, 95-96.	3.7	18

#	Article	IF	Citations
145	Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness. Pediatrics, 2016, 137, .	1.0	21
146	Childhood maltreatment and comorbid anxiety in people with bipolar disorder. Journal of Affective Disorders, 2016, 192, 22-27.	2.0	33
147	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.3	19
148	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. Biological Psychiatry, 2016, 79, 329-336.	0.7	21
149	Familiality and SNP heritability of age at onset and episodicity in major depressive disorder. Psychological Medicine, 2015, 45, 2215-2225.	2.7	21
150	Review of an innovative approach to practical trials: the â€˜cohort multiple RCTâ€™ design. Trials, 2015, 16, .	0.7	6
151	Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology, 2015, 232, 2609-2617.	1.5	31
152	The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25â€‰000 subjects. Molecular Psychiatry, 2015, 20, 735-743.	4.1	59
153	Neurotrophic factors in depression in response to treatment. Journal of Affective Disorders, 2015, 183, 287-294.	2.0	43
154	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	2.0	528
155	A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Medicine, 2015, 13, 86.	2.3	56
156	Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders. Neuron, 2015, 86, 1189-1202.	3.8	102
157	Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. European Neuropsychopharmacology, 2015, 25, 1578-1585.	0.3	5
158	Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2015, 2, 710-717.	3.7	113
159	Response to Kunte et al.. American Journal of Psychiatry, 2015, 172, 201-201.	4.0	1
160	Association of a Brain Methylation Site With Clinical Outcomes in Depression Does Not Replicate Across Populations. American Journal of Psychiatry, 2015, 172, 395-397.	4.0	3
161	Insulin resistance and outcome in bipolar disorder. British Journal of Psychiatry, 2015, 206, 52-57.	1.7	120
162	Provocation of Symmetry/Ordering Symptoms in Anorexia nervosa: A Functional Neuroimaging Study. PLoS ONE, 2014, 9, e97998.	1.1	11

#	Article	IF	Citations
163	GeneÃ¢â‚¬â€œEnvironment Interactions in Severe Mental Illness. Frontiers in Psychiatry, 2014, 5, 48.	1.3	204
164	Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 77-83.	1.1	16
165	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. American Journal of Psychiatry, 2014, 171, 1278-1286.	4.0	336
166	Investigation of blood mRNA biomarkers for suicidality in an independent sample. Translational Psychiatry, 2014, 4, e474-e474.	2.4	24
167	A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry, 2014, 14, 344.	1.1	74
168	Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychological Medicine, 2014, 44, 507-517.	2.7	99
169	Interaction between stress and the BDNFVal66Met polymorphism in depression: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 7.	2.3	228
170	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Psychopharmacology, 2014, 28, 142-150.	2.0	18
171	FUNCTIONAL POLYMORPHISM IN THE BRAIN-DERIVED NEUROTROPHIC FACTOR GENE INTERACTS WITH STRESSFUL LIFE EVENTS BUT NOT CHILDHOOD MALTREATMENT IN THE ETIOLOGY OF DEPRESSION. Depression and Anxiety, 2014, 31, 326-334.	2.0	37
172	MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH OF CHANGES FROM DSM-IV. Depression and Anxiety, 2014, 31, 459-471.	2.0	260
173	Risk of Mental Illness in Offspring of Parents With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Meta-Analysis of Family High-Risk Studies. Schizophrenia Bulletin, 2014, 40, 28-38.	2.3	544
174	Geneâ€“environment interactions in common mental disorders: an update and strategy for a genome-wide search. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 3-14.	1.6	74
175	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014, 28, 133-141.	2.0	75
176	Insulin Resistance, Diabetes Mellitus, and Brain Structure in Bipolar Disorders. Neuropsychopharmacology, 2014, 39, 2910-2918.	2.8	67
177	The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder. BMC Medicine, 2014, 12, 73.	2.3	52
178	Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genomeâ€wide association and polygenic scoring study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 428-437.	1.1	99
179	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 2014, 14, 395-399.	0.9	20
180	Epigenetic traces of childhood maltreatment in peripheral blood: a new strategy to explore geneâ€“environment interactions. British Journal of Psychiatry, 2014, 204, 3-5.	1.7	12

#	Article	IF	Citations
181	Increasing Cognitive Load Reduces Interference from Masked Appetitive and Aversive but Not Neutral Stimuli. PLoS ONE, 2014, 9, e94417.	1.1	17
182	Genome-wide association analysis of copy number variation in recurrent depressive disorder. Molecular Psychiatry, 2013, 18, 183-189.	4.1	45
183	SEROTONIN TRANSPORTER LENGTH POLYMORPHISM, CHILDHOOD MALTREATMENT, AND CHRONIC DEPRESSION: A SPECIFIC GENE-ENVIRONMENT INTERACTION. Depression and Anxiety, 2013, 30, 5-13.	2.0	55
184	Contribution of Common Genetic Variants to Antidepressant Response. Biological Psychiatry, 2013, 73, 679-682.	0.7	199
185	Genomeâ€wide association analysis accounting for environmental factors through propensityâ€score matching: Application to stressful live events in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 521-529.	1.1	16
186	Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. European Neuropsychopharmacology, 2013, 23, 653-662.	0.3	32
187	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology, 2013, 23, 1105-1114.	0.3	68
188	P.4.002 Genetic differences in drug-metabolising enzymes: can they be used to predict antidepressant treatment response?. European Neuropsychopharmacology, 2013, 23, S69-S70.	0.3	0
189	Why negative meta-analyses may be false?. European Neuropsychopharmacology, 2013, 23, 1307-1309.	0.3	6
190	The interaction between child maltreatment, adult stressful life events and the 5-HTTLPR in major depression. Journal of Psychiatric Research, 2013, 47, 1032-1035.	1.5	21
191	Interaction between specific forms of childhood maltreatment and the serotonin transporter gene (5-HTT) in recurrent depressive disorder. Journal of Affective Disorders, 2013, 145, 136-141.	2.0	39
192	A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 2013, 18, 497-511.	4.1	1,002
193	A genome-wide association study of a sustained pattern of antidepressant response. Journal of Psychiatric Research, 2013, 47, 1157-1165.	1.5	52
194	Brain Structural Signature of Familial Predisposition for Bipolar Disorder: Replicable Evidence For Involvement of the Right Inferior Frontal Gyrus. Biological Psychiatry, 2013, 73, 144-152.	0.7	118
195	Brain responses to body image stimuli but not food are altered in women with bulimia nervosa. BMC Psychiatry, 2013, 13, 302.	1.1	28
196	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8708-8713.	3.3	272
197	Genome-wide association study of co-occurring anxiety in major depression. World Journal of Biological Psychiatry, 2013, 14, 611-621.	1.3	17
198	Fecundity of Patients With Schizophrenia, Autism, Bipolar Disorder, Depression, Anorexia Nervosa, or Substance Abuse vs Their Unaffected Siblings. JAMA Psychiatry, 2013, 70, 22.	6.0	284

#	Article	IF	Citations
199	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	4.0	216
200	Typology of clinical course in bipolar disorder based on 18-month naturalistic follow-up. Psychological Medicine, 2013, 43, 789-799.	2.7	15
201	Genomics and the classification of mental illness: focus on broader categories. Genome Medicine, 2013, 5, 97.	3.6	12
202	Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder. Pharmacogenomics, 2013, 14, 1979-1990.	0.6	55
203	Functional neuroanatomy of body checking in people with anorexia nervosa. International Journal of Eating Disorders, 2013, 46, 653-662.	2.1	17
204	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of Psychopharmacology, 2013, 27, 915-920.	2.0	31
205	DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Translational Psychiatry, 2013, 3, e300-e300.	2.4	71
206	Antidepressant effects of nortriptyline and escitalopram in the <scp>GENDEP</scp> study: Is one better than the other?. Acta Psychiatrica Scandinavica, 2013, 127, 330-330.	2.2	1
207	Revision of ICD â€“ status update on feeding and eating disorders. Advances in Eating Disorders (Abingdon, England), 2013, 1, 10-20.	0.8	51
208	Decision-making and â€˜gut feelingâ€™ in males with anorexia nervosa. Advances in Eating Disorders (Abingdon, England), 2013, 1, 51-60.	0.8	1
209	ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. Journal of Psychopharmacology, 2013, 27, 609-615.	2.0	20
210	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline â€˜Predictorsâ€™ and Longitudinal â€˜Targetsâ€™. Neuropsychopharmacology, 2013, 38, 377-385.	2.8	372
211	Estimating the heritability of reporting stressful life events captured by common genetic variants. Psychological Medicine, 2013, 43, 1965-1971.	2.7	46
212	The Changing Understanding of the Genetic and Environmental Causes of Mental Illness. Canadian Journal of Psychiatry, 2013, 58, 67-68.	0.9	3
213	The Impact of Phenotypic and Genetic Heterogeneity on Results of Genome Wide Association Studies of Complex Diseases. PLoS ONE, 2013, 8, e76295.	1.1	177
214	Classification issues and challenges in child and adolescent psychopathology. International Review of Psychiatry, 2012, 24, 514-529.	1.4	27
215	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	3.9	110
216	Relative impact of maternal depression and associated risk factors on offspring psychopathology. British Journal of Psychiatry, 2012, 200, 124-129.	1.7	134

#	Article	IF	Citations
217	Interaction between the BDNF gene Val/66/Met polymorphism and morning cortisol levels as a predictor of depression in adult women. British Journal of Psychiatry, 2012, 201, 313-319.	1.7	27
218	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
219	Therapygenetics: the 5HTTLPR and response to psychological therapy. Molecular Psychiatry, 2012, 17, 236-237.	4.1	135
220	Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological Medicine, 2012, 42, 2027-2035.	2.7	30
221	Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis. American Journal of Psychiatry, 2012, 169, 141-151.	4.0	1,103
222	Basing psychiatric classification on scientific foundation: Problems and prospects. International Review of Psychiatry, 2012, 24, 591-605.	1.4	54
223	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine, 2012, 42, 967-980.	2.7	298
224	P.4.015 Gene expression profile associated with major depression and with antidepressant response. European Neuropsychopharmacology, 2012, 22, S95-S96.	0.3	0
225	Non-random dropout and the relative efficacy of escitalopram and nortriptyline inÂtreating major depressive disorder. Journal of Psychiatric Research, 2012, 46, 1333-1338.	1.5	12
226	The role of loss and danger events in symptom exacerbation in bipolar disorder. Journal of Psychiatric Research, 2012, 46, 1584-1589.	1.5	32
227	Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response. Genome Medicine, 2012, 4, 52.	3.6	16
228	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	0.9	92
229	Dissecting the Genetic Heterogeneity of Depression Through Age at Onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 859-868.	1.1	31
230	SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?. Depression and Anxiety, 2012, 29, 1043-1049.	2.0	182
231	Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics, 2012, 12, 2355-2365.	1.3	18
232	Subliminal food images compromise superior working memory performance in women with restricting anorexia nervosa. Consciousness and Cognition, 2012, 21, 751-763.	0.8	35
233	Classification of feeding and eating disorders: review of evidence and proposals for ICDâ€11. World Psychiatry, 2012, 11, 80-92.	4.8	125
234	Biomarkers predicting treatment outcome in depression: what is clinically significant?. Pharmacogenomics, 2012, 13, 233-240.	0.6	44

#	Article	IF	Citations
235	NEUROTICISM MEDIATES THE EFFECT OF P2RX7 ON OUTCOMES OF MOOD DISORDERS. Depression and Anxiety, 2012, 29, 816-823.	2.0	14
236	Geneâ€“Environment Interaction in Major Depression and Antidepressant Treatment Response. Current Psychiatry Reports, 2012, 14, 129-137.	2.1	82
237	Depressive disorder moderates the effect of the FTO gene on body mass index. Molecular Psychiatry, 2012, 17, 604-611.	4.1	72
238	Stressful life events and the serotonin transporter gene (5-HTT) in recurrent clinical depression. Journal of Affective Disorders, 2012, 136, 189-193.	2.0	22
239	Poor Decision Making in Male Patients with Anorexia Nervosa. European Eating Disorders Review, 2012, 20, 169-173.	2.3	43
240	Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenetics and Genomics, 2012, 22, 765-776.	0.7	28
241	Thinking about Eating Food Activates Visual Cortex with Reduced Bilateral Cerebellar Activation in Females with Anorexia Nervosa: An fMRI Study. PLoS ONE, 2012, 7, e34000.	1.1	80
242	Do Suicidal Thoughts or Behaviors Recur During a Second Antidepressant Treatment Trial?. Journal of Clinical Psychiatry, 2012, 73, 1439-1442.	1.1	8
243	Are children of depressed mothers exposed to higher contextual, family and mother-based risks?. European Psychiatry, 2011, 26, 1193-1193.	0.1	0
244	Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants. Biological Psychiatry, 2011, 69, 360-365.	0.7	30
245	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 2011, 12, 365-377.	0.6	49
246	Genes, Environment, and Individual Differences in Responding to Treatment for Depression. Harvard Review of Psychiatry, 2011, 19, 109-124.	0.9	78
247	Differential Neural Responses to Food Images in Women with Bulimia versus Anorexia Nervosa. PLoS ONE, 2011, 6, e22259.	1.1	187
248	Genomewide Association Scan of Suicidal Thoughts and Behaviour in Major Depression. PLoS ONE, 2011, 6, e20690.	1.1	98
249	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders, 2011, 132, 112-120.	2.0	93
250	Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: Replications and implications for resolving inconsistent results. Journal of Affective Disorders, 2011, 135, 56-65.	2.0	136
251	Reactivity of affect and self-esteem during remission in bipolar affective disorder: An experimental investigation. Journal of Affective Disorders, 2011, 134, 102-111.	2.0	32
252	The contribution of prenatal and postnatal maternal anxiety and depression to child maladjustment. Depression and Anxiety, 2011, 28, 696-702.	2.0	234

#	Article	IF	Citations
253	Eating disorders, geneâ€“environment interactions and epigenetics. Neuroscience and Biobehavioral Reviews, 2011, 35, 784-793.	2.9	108
254	The truth about genetic variation in the serotonin transporter gene and response to stress and medication. British Journal of Psychiatry, 2011, 198, 424-427.	1.7	44
255	Changes in body weight during pharmacological treatment of depression. International Journal of Neuropsychopharmacology, 2011, 14, 367-375.	1.0	41
256	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	2.0	44
257	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2011, 11, 138-145.	0.9	70
258	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the5-HTTLPR. World Journal of Biological Psychiatry, 2011, 12, 528-538.	1.3	31
259	Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression. Journal of Clinical Psychiatry, 2011, 72, 1478-1484.	1.1	117
260	The Everyday Feeling Questionnaire: the structure and validation of a measure of general psychological well-being and distress. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 413-423.	1.6	31
261	Trends in hospital admissions for eating disorders in a country undergoing a socio-cultural transition, the Czech Republic 1981â€“2005. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 541-550.	1.6	33
262	Neural correlates of body dissatisfaction in anorexia nervosa. Neuropsychologia, 2010, 48, 2878-2885.	0.7	118
263	Antidepressants, social adversity and outcome of depression in general practice. Journal of Affective Disorders, 2010, 121, 239-246.	2.0	27
264	History of suicide attempts among patients with depression in the GENDEP project. Journal of Affective Disorders, 2010, 123, 131-137.	2.0	18
265	Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. Journal of Affective Disorders, 2010, 125, 345-349.	2.0	68
266	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of Affective Disorders, 2010, 127, 337-342.	2.0	32
267	The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Molecular Psychiatry, 2010, 15, 18-22.	4.1	373
268	Genome-Wide Association Study of Major Recurrent Depression in the U.K. Population. American Journal of Psychiatry, 2010, 167, 949-957.	4.0	221
269	Genetic Sensitivity to the Environment: The Case of the Serotonin Transporter Gene and Its Implications for Studying Complex Diseases and Traits. American Journal of Psychiatry, 2010, 167, 509-527.	4.0	1,260
270	Predictors of Response and Drop-Out During Intensive Dialectical Behavior Therapy. Journal of Personality Disorders, 2010, 24, 634-650.	0.8	37

#	Article	IF	Citations
271	Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine, 2010, 40, 1367-1377.	2.7	107
272	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. American Journal of Psychiatry, 2010, 167, 555-564.	4.0	314
273	Genetic Sensitivity to the Environment: The Case of the Serotonin Transporter Gene and Its Implications for Studying Complex Diseases and Traits. Focus (American Psychiatric Publishing), 2010, 8, 398-416.	0.4	45
274	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	13.8	118
275	Probing the Genome to Understand Suicide. American Journal of Psychiatry, 2010, 167, 1425-1427.	4.0	6
276	Repetitive Transcranial Magnetic Stimulation Reduces Cue-Induced Food Craving in Bulimic Disorders. Biological Psychiatry, 2010, 67, 793-795.	0.7	147
277	The genetics of affective disorder and suicide. European Psychiatry, 2010, 25, 275-277.	0.1	55
278	Adverse reactions to antidepressants. British Journal of Psychiatry, 2009, 195, 202-210.	1.7	205
279	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	1.7	143
280	Protective Effect of CRHR1 Gene Variants on the Development of Adult Depression Following Childhood Maltreatment. Archives of General Psychiatry, 2009, 66, 978.	13.8	260
281	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Medicine, 2009, 7, 60.	2.3	43
282	Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders, 2009, 118, 147-154.	2.0	89
283	The role of genetic variation in the causation of mental illness: an evolution-informed framework. Molecular Psychiatry, 2009, 14, 1072-1082.	4.1	192
284	Stability of symptoms across major depressive episodes in bipolar disorder. Bipolar Disorders, 2009, 11, 867-875.	1.1	17
285	Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2009, 9, 225-233.	0.9	188
286	An examination of decision making in bulimia nervosa. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 455-461.	0.8	63
287	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology, 2009, 34, 2517-2528.	2.8	105
288	P.3.13 Temperament and character of subjects with treatment increase suicidal ideations in the GENDEP study. European Neuropsychopharmacology, 2009, 19, S72-S73.	0.3	0

#	Article	IF	Citations
289	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 2009, 194, 252-259.	1.7	170
290	It would not have happened to me at home: qualitative exploration of sojourns abroad and eating disorders in young Czech women. European Eating Disorders Review, 2008, 16, 207-214.	2.3	12
291	The implications of geneâ€“environment interactions in depression: will cause inform cure?. Molecular Psychiatry, 2008, 13, 1070-1078.	4.1	128
292	The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Molecular Psychiatry, 2008, 13, 131-146.	4.1	455
293	Self-, parent-report and interview measures of obsessiveâ€“compulsive disorder in children and adolescents. Journal of Anxiety Disorders, 2008, 22, 979-990.	1.5	52
294	Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine, 2008, 38, 289-300.	2.7	227
295	The inability to ignore: distractibility in women with restricting anorexia nervosa. Psychological Medicine, 2008, 38, 1741-1748.	2.7	32
296	Forum: the case for geneâ€“environment interactions in psychiatry. Current Opinion in Psychiatry, 2008, 21, 318-321.	3.1	13
297	Gene-Environment Interaction: Overcoming Methodological Challenges. Novartis Foundation Symposium, 2008, 293, 13-30.	1.2	20
298	An investigation of decision making in anorexia nervosa using the Iowa Gambling Task and skin conductance measurements. Journal of the International Neuropsychological Society, 2007, 13, 635-41.	1.2	131
299	Screening young people for obsessive-compulsive disorder. British Journal of Psychiatry, 2007, 191, 353-354.	1.7	48
300	Iâ€™m not as slim as that girl: Neural bases of body shape self-comparison to media images. NeuroImage, 2007, 37, 674-681.	2.1	69
301	Cerebral processing of food-related stimuli: Effects of fasting and gender. Behavioural Brain Research, 2006, 169, 111-119.	1.2	223
302	Managing patients' information in a community mental health team. Psychiatric Bulletin, 2006, 30, 172-174.	0.3	1
303	Differential motivational responses to food and pleasurable cues in anorexia and bulimia nervosa: a startle reflex paradigm. Psychological Medicine, 2006, 36, 1327-1335.	2.7	128
304	Personality Pathology Among Individuals With a Lifetime History of Anorexia Nervosa. Journal of Personality Disorders, 2006, 20, 417-430.	0.8	58
305	Use of Socioeconomic Status in Health Research. JAMA - Journal of the American Medical Association, 2006, 295, 1770.	3.8	4
306	Hallucinations during lamotrigine treatment of bipolar disorder. American Journal of Psychiatry, 2006, 163, 749-50.	4.0	4

#	Article	IF	Citations
307	Elevated pain threshold in eating disorders: physiological and psychological factors. Journal of Psychiatric Research, 2005, 39, 431-438.	1.5	75
308	Brain lesions and eating disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 852-857.	0.9	139
309	Effect of Left Prefrontal Repetitive Transcranial Magnetic Stimulation on Food Craving. Biological Psychiatry, 2005, 58, 840-842.	0.7	156
310	Functional Neuroanatomy of Body Shape Perception in Healthy and Eating-Disordered Women. Biological Psychiatry, 2005, 58, 990-997.	0.7	225
311	Medial Prefrontal Cortex Activity Associated With Symptom Provocation in Eating Disorders. American Journal of Psychiatry, 2004, 161, 1238-1246.	4.0	421
312	Recovery and chronicity in anorexia nervosa. Biological Psychiatry, 2003, 54, 934-942.	0.7	203
313	Neuroimaging and Eating Disorders. , 2003, , 171-190.		1
314	Neuroanatomical Bases of Eating Disorders. , 0, , 1173-1179.		9